文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

玻璃体腔抗血管内皮生长因子治疗化疗后视网膜母细胞瘤新生血管的长期结果

INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE MANAGEMENT OF NEOVASCULARIZATION IN RETINOBLASTOMA AFTER INTRAVENOUS AND/OR INTRAARTERIAL CHEMOTHERAPY: Long-Term Outcomes in a Series of 35 Eyes.
PubMed 文献 · Retina · 2019-01-01

回顾性分析35只眼(33例患者)在静脉和/或动脉化疗后出现虹膜和/或视网膜新生血管,接受至少一次玻璃体腔抗血管内皮生长因子(抗VEGF)治疗。新生血管消退28眼(80%),眼球保留率51%,无眼外扩散或转移。

要点

  • 多数眼为D或E组,常见视网膜缺血(94%)和视网膜脱离(51%)。
  • 平均每眼1.6次抗VEGF注射,80%新生血管消退,51%眼球保留。
  • 无眼外扩散或转移,平均随访3.7年。

核心结论

  • 玻璃体腔抗VEGF有助于创造继续保守治疗的条件,使眼球保留率达到51%。

研究设计与样本

  • 回顾性系列报告,纳入35只眼(33例患者),至少接受一次玻璃体腔抗VEGF(雷珠单抗和/或阿柏西普)治疗静脉化疗和/或动脉化疗后的虹膜和/或视网膜新生血管。

主要发现

  • 31/35眼(89%)为D或E组;既往治疗包括静脉化疗后挽救性动脉化疗(21/35,60%)、一线动脉化疗(7/35,20%)、一线静脉化疗(7/35,20%)。
  • 伴随临床特征包括视网膜缺血(94%)、视网膜脱离(51%)、活动性肿瘤(34%)、玻璃体出血(43%)和/或青光眼(17%)。
  • 平均每眼接受1.6次抗VEGF注射;28眼接受雷珠单抗,2眼接受阿柏西普,5眼接受两者。
  • 新生血管消退见于28眼(28/35,80%);眼球保留为51%(18/35),其中活动性肿瘤眼为25%(3/12)。

临床怎么用

  • 对于化疗后出现虹膜或视网膜新生血管的视网膜母细胞瘤眼,可考虑玻璃体腔抗VEGF作为辅助治疗以创造继续保守治疗的条件。

局限性

  • 回顾性设计,样本量有限(35眼),抗VEGF药物和剂量不完全统一,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the use of anti-vascular endothelial growth factor in the management of retinoblastoma. METHODS: Retrospective review of 35 eyes (33 patients) treated with at least one intravitreal anti-vascular endothelial growth factor (ranibizumab and/or aflibercept) for new iris (n = 26) and/or retinal neovascularization (n = 21) after intravenous chemotherapy and/or intraarterial chemotherapy. RESULTS: Most eyes (n = 31/35, 89%) were Group D or E. Previous treatments were salvage intraarterial chemotherapy after intravenous chemotherapy (n = 21/35, 60%), first-line intraarterial chemotherapy (n = 7/35, 20%), and first-line intravenous chemotherapy (n = 7/35, 20%). Associated clinical features were retinal ischemia (94%), retinal detachment (51%), active tumor (34%), intravitreal hemorrhage (43%), and/or glaucoma (17%). Mean 1.6 anti-vascular endothelial growth factor injections/eye were given; 28 eyes received ranibizumab, 2 aflibercept, and 5 both agents. Eight eyes underwent complementary treatments of ischemic retina. Resolution of neovascularization was observed in 28 eyes (n = 28/35, 80%). Globe salvage was achieved in 51% (n = 18/35), including 25% of those with active tumor (n = 3/12). One eye became phthisic. Sixteen eyes were enucleated, nine for tumor relapse/progression. Five eyes had high-risk histopathologic risk factors and received adjuvant intravenous chemotherapy. All patients are alive with no extraocular extension nor metastases (mean follow-up 3.7 years, range 1.1-7.6). CONCLUSION: Intravitreal anti-vascular endothelial growth factor contributed to a globe salvage rate of 51% by providing conditions to continue conservative treatment.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Stathopoulos C, Gaillard MC, Moulin A, et al. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE MANAGEMENT OF NEOVASCULARIZATION IN RETINOBLASTOMA AFTER INTRAVENOUS AND/OR INTRAARTERIAL CHEMOTHERAPY: Long-Term Outcomes in a Series of 35 Eyes. Retina. 2019. PMID: 30312257. doi:10.1097/IAE.0000000000002339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。